Production (Stage)
Enanta Pharmaceuticals, Inc.
ENTA
$7.50
$0.091.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -11.99% | 16.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.99% | 16.10% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -11.99% | 16.10% | |||
| SG&A Expenses | -11.35% | -6.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.59% | -8.90% | |||
| Operating Income | -4.18% | 21.14% | |||
| Income Before Tax | -5.47% | 22.20% | |||
| Income Tax Expenses | -213.70% | -14.60% | |||
| Earnings from Continuing Operations | -1.59% | 22.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.59% | 22.67% | |||
| EBIT | -4.18% | 21.14% | |||
| EBITDA | -2.96% | 22.88% | |||
| EPS Basic | -1.04% | 22.84% | |||
| Normalized Basic EPS | -7.90% | 27.37% | |||
| EPS Diluted | -1.04% | 22.84% | |||
| Normalized Diluted EPS | -7.90% | 27.37% | |||
| Average Basic Shares Outstanding | 0.55% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.55% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||